Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose-Reference-Cited by-同舟云学术

Renal risk-benefit determinants of recombinant human erythropoietin therapy in the remnant kidney rat model - hypertension, anaemia, inflammation and drug dose

Published:2016-02-17 Issue:3 Volume:43 Page:343-354
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

Ribeiro Sandra¹,Garrido Patrícia²³,Fernandes João²³,Vala Helena⁴,Rocha-Pereira Petronila⁵,Costa Elísio¹,Belo Luís¹,Reis Flávio²³,Santos-Silva Alice¹

Affiliation:

1. Research Unit on Applied Molecular Biosciences (UCIBIO); REQUIMTE; Department of Biological Sciences; Laboratory of Biochemistry; Faculty of Pharmacy; University of Porto; Porto Portugal

2. Laboratory of Pharmacology & Experimental Therapeutics; Institute for Biomedical Imaging and Life Sciences (IBILI); Faculty of Medicine; University of Coimbra; Coimbra Portugal

3. Centre for Neuroscience and Cell Biology - Institute for Biomedical Imaging and Life Sciences (CNC.IBILI) Research Unit; University of Coimbra; Coimbra Portugal

4. Centre for Studies in Education; Technologies and Health (CI&DETS); CITAB; Agrarian School of Viseu; Polytechnic Institute of Viseu; Viseu Portugal

5. Health Sciences Research Centre; Faculty of Health Sciences; University of Beira Interior; Covilhã Portugal

Funder

Fundação para a Ciência e a Tecnologia

QREN/FEDER

POPH/FSE

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1440-1681.12541/fullpdf

Reference51 articles.